JPH07215837A - Skin external agent - Google Patents

Skin external agent

Info

Publication number
JPH07215837A
JPH07215837A JP3308494A JP3308494A JPH07215837A JP H07215837 A JPH07215837 A JP H07215837A JP 3308494 A JP3308494 A JP 3308494A JP 3308494 A JP3308494 A JP 3308494A JP H07215837 A JPH07215837 A JP H07215837A
Authority
JP
Japan
Prior art keywords
keratinization
skin
added
solvent
emulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3308494A
Other languages
Japanese (ja)
Inventor
Keiichi Nishimura
桂一 西村
Yoshio Kitada
好男 北田
Toshiyuki Fukuda
寿之 福田
Makoto Yamamoto
信 山本
Toshio Miyase
敏男 宮瀬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Chemical Industries Inc
Original Assignee
Pola Chemical Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Chemical Industries Inc filed Critical Pola Chemical Industries Inc
Priority to JP3308494A priority Critical patent/JPH07215837A/en
Publication of JPH07215837A publication Critical patent/JPH07215837A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE:To obtain a keratinization simulation-inhibiting agent high in safety, excellent in a skin roughness-improving action, and useful as an ingredient for cosmetics. CONSTITUTION:A keratinization stimulation-inhibiting agent comprises 1,2- dihydroxy-4-(2-hydroxyethyl)benzene of the formula and/or its salt. The compound is added in an amount of 0.1-10wt.% to a skin external agent. The compound is obtained by isolation from Stachys and subsequently purifying the isolated compound by a general purification method such as column chromatography, or extracting the whole grasses of the fresh or dried Stachys with a solvent, removing impurities from the extract by a filtration method, etc., removing the solvent from the obtained filtrate, and subsequently purifying the residue by the purification means.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は角化亢進抑制剤及びそれ
を含有する皮膚外用剤に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a hyperkeratosis inhibitor and a skin external preparation containing the same.

【0002】[0002]

【従来の技術】表皮最外層は、角化細胞の細胞膜が強固
に肥厚して分化した角質細胞が積層してできており、こ
の積層した角質細胞によって、生体は物理的或いは化学
的ダメージから守られている。従って、この角層は防御
機能を担っているが故に、常に角化細胞の角化と角質細
胞の剥離、脱落(ターンオーバー)により常にその防御
機能が一定になるように保たれている。
2. Description of the Related Art The outermost layer of the epidermis is formed by stacking keratinocytes that are strongly thickened and differentiated from the cell membrane of keratinocytes, and the stacked keratinocytes protect the living body from physical or chemical damage. Has been. Therefore, since the stratum corneum has a protective function, the protective function is always kept constant by keratinization of keratinocytes and exfoliation and turn-off of keratinocytes (turnover).

【0003】しかし、角質細胞が著しく損傷を受けた
り、身体の栄養或いは代謝のバランスが崩れると、角化
亢進が起こり、角質細胞が過剰に生成されて、角質肥厚
が起こったり、角化が完全に終了できない角化不全の細
胞が角層に蓄積したり、肌荒れ、シワ等の問題が起こっ
てくる。
[0003] However, when keratinocytes are significantly damaged or the nutritional or metabolic balance of the body is lost, keratinization is promoted, keratinocytes are excessively produced, keratin thickening occurs, and keratinization is complete. Insufficient keratinization cells that cannot be completed will accumulate in the stratum corneum, and problems such as rough skin and wrinkles will occur.

【0004】従来、このような角化亢進に対しては、肌
あれやシワについて、主に皮膚角層の水分量をコントロ
ールする方向で、対症的に対応がなされてきた。例え
ば、皮膚との親和性が良く、疎水性を有する閉塞剤を用
いて角層水分の蒸散を抑制し、角層中に水分を貯留させ
る方法や、ヒアルロン酸に代表される、水分保持力の高
い多糖類を保湿剤として用い、皮膚水和効果を高める方
法は、何れもこの角層中の水分保持により、肌あれやシ
ワを改善することを目指した物である。
Conventionally, such hyperkeratosis has been treated symptomatically with regard to skin roughness and wrinkles, mainly in the direction of controlling the amount of water in the stratum corneum of the skin. For example, a method of suppressing evaporation of water in the stratum corneum by using an occlusive agent having a good affinity with the skin and having hydrophobicity, and a method of storing moisture in the stratum corneum, and a method of retaining moisture such as hyaluronic acid All of the methods using a high polysaccharide as a moisturizer to enhance the skin hydration effect are aimed at improving skin roughness and wrinkles by retaining water in the stratum corneum.

【0005】しかし、これらの物質では、角層内の水分
の散逸はある程度防止できても、角化亢進に対しては何
等作用を及ぼさないので、これによる角質肥厚や角化不
全に対して、全く為すすべがなかった。
However, these substances have no effect on the promotion of keratinization even though the dissipation of water in the stratum corneum can be prevented to some extent. There was nothing to do.

【0006】[0006]

【発明が解決しようとする課題】本発明は、上記実状に
鑑みて為された物であり、皮膚の角化亢進を充分に抑制
し、肌あれやシワ等の皮膚の状態変化を改善する作用を
有する角化亢進抑制剤及びこれを含有する皮膚外用剤を
提供することを課題とする。
DISCLOSURE OF THE INVENTION The present invention has been made in view of the above-mentioned circumstances, and has an effect of sufficiently suppressing keratinization of the skin and improving changes in the skin condition such as skin roughness and wrinkles. It is an object of the present invention to provide a keratinization-promoting inhibitor having the above and a skin external preparation containing the same.

【0007】[0007]

【課題を解決するための手段】本発明者らは、上記課題
を解決するために、各種化学物質について、幅広く角化
亢進抑制作用を指標にスクリーニングを行った。その結
果、構造式化2に示される1、2−ジヒドロキシ−4−
(2−ヒドロキシエチル)ベンゼンに優れた角化亢進抑
制作用があるのを見いだし、発明を完成させた。
[Means for Solving the Problems] In order to solve the above problems, the present inventors have screened various chemical substances with a broad keratinization-suppressing action as an index. As a result, 1,2-dihydroxy-4- shown in Structural Formula 2 was obtained.
The inventors have found that (2-hydroxyethyl) benzene has an excellent effect of suppressing hyperkeratosis, and completed the invention.

【0008】[0008]

【化2】 [Chemical 2]

【0009】即ち、本発明は構造式化1に示される1、
2−ジヒドロキシ−4−(2−ヒドロキシエチル)ベン
ゼン及び/またはその塩からなる角化亢進抑制剤及びこ
れを0.1化ら0重量%含有する皮膚外用剤に関する。
That is, the present invention is 1, which is shown in Structural Formula 1,
The present invention relates to a keratinization-suppressing agent consisting of 2-dihydroxy-4- (2-hydroxyethyl) benzene and / or a salt thereof and an external preparation for skin containing 0.1% by weight of 0.1%.

【0010】以下、本発明について詳細に説明をする。The present invention will be described in detail below.

【0011】本発明の角化亢進抑制剤である1、2−ジ
ヒドロキシ−4−(2−ヒドロキシエチル)ベンゼンは
シソ科の植物である、イヌゴマ中より単離された。イヌ
ゴマより、この物質を得るには、生又は乾燥したイヌゴ
マの全草を溶媒で抽出し、この抽出物からろ過等で不溶
物を除き、得られた濾液から溶媒を留去した後、カラム
クロマトグラフィー等の一般的な精製手段を用いて精製
すれば良い。
1,2-Dihydroxy-4- (2-hydroxyethyl) benzene, which is a keratinization-promoting inhibitor of the present invention, was isolated from sesame, a plant of the Labiatae family. In order to obtain this substance from sesame seeds, whole grass of dried or sesame seeds is extracted with a solvent, insoluble matter is removed from this extract by filtration, etc., and the solvent is distilled off from the obtained filtrate, followed by column chromatography. It may be purified using a general purifying means such as chromatography.

【0012】このとき、抽出は連続抽出法でも、バッチ
式抽出法でも良く、室温下数日、或いは沸点付近の温度
まで加熱して数時間、溶媒中に浸漬しておけば良い。こ
の時攪拌を加えればより好ましい。
At this time, the extraction may be a continuous extraction method or a batch extraction method, and may be carried out at room temperature for several days, or may be heated to a temperature near the boiling point and immersed in a solvent for several hours. It is more preferable to add stirring at this time.

【0013】抽出に用いる溶媒としては、極性溶媒が好
ましく、例えば、メタノール、エタノール等のアルコー
ル類、アセトンやメチルエチルケトン等のケトン類、ク
ロロホルム、ジクロロメタン等のハロゲン化炭化水素
類、ジエチルエーテル、イソプロピルエーテル等のエー
テル類が挙げられ、これらをただ1種用いても、2種以
上を混合して用いても良い。
The solvent used for extraction is preferably a polar solvent, for example, alcohols such as methanol and ethanol, ketones such as acetone and methyl ethyl ketone, halogenated hydrocarbons such as chloroform and dichloromethane, diethyl ether, isopropyl ether and the like. The ethers may be used, and these may be used alone or in combination of two or more.

【0014】本発明の角化亢進抑制剤には、上記の様に
して得られる1、2−ジヒドロキシ−4−(2−ヒドロ
キシエチル)ベンゼンの他にこの化合物の塩を用いるこ
ともできる。この場合、1、2−ジヒドロキシ−4−
(2−ヒドロキシエチル)ベンゼン及びこの塩の内の1
種を単独で用いても、或いはこれらから選ばれる2種以
上を混合して用いても良い。
In addition to 1,2-dihydroxy-4- (2-hydroxyethyl) benzene obtained as described above, salts of this compound can be used in the keratinization-promoting agent of the present invention. In this case 1,2-dihydroxy-4-
(2-hydroxyethyl) benzene and one of its salts
The seeds may be used alone, or two or more kinds selected from these may be mixed and used.

【0015】また、この様な本発明で使用可能な塩とし
ては、1、2−ジヒドロキシ−4−(2−ヒドロキシエ
チル)ベンゼンと無機或いは有機の塩基を等量で反応さ
せて得られる、ナトリウム、カリウム等のアルカリ金属
との塩、カルシウム、マグネシウム等のアルカリ土類金
属との塩、アンモニア、トリエチルアミン等のアミン類
との塩、アルギニン、リジン等の塩基性アミノ酸との塩
等が例示できる。
As the salt usable in the present invention, sodium obtained by reacting 1,2-dihydroxy-4- (2-hydroxyethyl) benzene with an inorganic or organic base in equal amounts is used. , Salts with alkali metals such as potassium, salts with alkaline earth metals such as calcium and magnesium, salts with amines such as ammonia and triethylamine, and salts with basic amino acids such as arginine and lysine.

【0016】本発明の皮膚外用剤は、上記角化亢進抑制
剤を0.1〜10重量%含有する物である。角化亢進抑
制剤を皮膚外用剤ちゅうに配合するのは、常法に則って
配合すれば良く、配合に際して、共に用いることのでき
る任意成分として、皮膚外用剤に一般的に用いられる、
水性成分、油性成分、粉末成分、界面活性剤、保湿剤、
増粘剤、色剤、香料、防腐剤、抗酸化剤、pH調整剤、
キレート剤、紫外線吸収剤、抗炎症剤、ホルモン、核酸
類、各種ビタミン類が例示できる。
The external preparation for skin of the present invention contains 0.1 to 10% by weight of the above-mentioned keratinization inhibiting agent. The keratinization-promoting inhibitor may be added to the external skin preparation as long as it is added in accordance with a conventional method, and when it is added, it is generally used as an external preparation for skin as an optional component that can be used together.
Aqueous component, oil component, powder component, surfactant, moisturizer,
Thickener, colorant, fragrance, antiseptic, antioxidant, pH adjuster,
Examples include chelating agents, ultraviolet absorbers, anti-inflammatory agents, hormones, nucleic acids, and various vitamins.

【0017】本発明に於ける、上記角化亢進抑制剤の好
ましい配合量は0.1〜10重量%である。これは、
0.1重量%未満では角化亢進抑制効果は充分得られ
ず、10重量%を越えても効果は頭打ちで経済的でない
からである。
In the present invention, the compounding amount of the keratinization-promoting inhibitor is preferably 0.1 to 10% by weight. this is,
This is because if it is less than 0.1% by weight, the effect of suppressing hyperkeratosis is not sufficiently obtained, and if it exceeds 10% by weight, the effect is flat and not economical.

【実施例】【Example】

【0018】以下に実施例を挙げて、本発明について更
に詳しく述べるが、本発明がこれら実施例に何等限定を
受けないことは言うまでもない。
Hereinafter, the present invention will be described in more detail with reference to Examples, but it goes without saying that the present invention is not limited to these Examples.

【0019】実施例1 角化亢進抑制剤の製造例 イヌゴマの乾燥物10Kgを細かく細断し、これに5l
のエタノールと5lの精製水を加え、攪拌しながら3時
間加熱還流した。その後、抽出液を冷却し、濾過して不
溶物を除去した。この濾液を減圧乾固し、それをあらた
めて精製水に溶解させ、ダイヤイオンHP−20(三菱
化成(株)製)を充填したカラムに流し、更に精製水2
lを流しこれを洗浄した。この後、エタノール2lを流
し、吸着物を溶出させ、これを減圧乾固し、分取高速液
体クロマトグラフィー((株)東ソー製、HLC83
7、ODSカラム、溶出溶媒:5→50%アセトニトリ
ル水溶液、検知:紫外部220nm)で精製し、本発明
の角化亢進抑制剤である1、2−ジヒドロキシ−4−
(2−ヒドロキシエチル)ベンゼンを263mg得た。
Example 1 Production example of keratinization-suppressing agent 10 kg of dried sesame seeds was finely chopped into 5 liters.
Of ethanol and 5 l of purified water were added, and the mixture was heated under reflux for 3 hours with stirring. Then, the extract was cooled and filtered to remove insoluble matter. The filtrate was evaporated to dryness under reduced pressure, dissolved again in purified water, passed through a column packed with Diaion HP-20 (manufactured by Mitsubishi Kasei Co., Ltd.), and further purified water 2
This was washed by pouring l. Thereafter, 2 l of ethanol was poured to elute the adsorbed substance, which was dried under reduced pressure, and then subjected to preparative high performance liquid chromatography (manufactured by Tosoh Corp., HLC83).
7, ODS column, elution solvent: 5 → 50% acetonitrile aqueous solution, detection: UV 220 nm), and 1,2-dihydroxy-4-which is a keratinization-promoting inhibitor of the present invention.
263 mg of (2-hydroxyethyl) benzene was obtained.

【0020】実施例2 急性毒性 6匹のICRマウス(雄性、体重25〜35g)の腹腔
内に、実施例1で得られた角化亢進抑制剤の10%生理
食塩水溶液を、それぞれ1000mg/Kg注射した。
投与後14日に生死を判定したが、死亡例は認められな
かった。これより本発明の角化亢進抑制剤はLD50値は
1000mg/Kgであり、安全性が高いことが分か
る。
Example 2 Acute toxicity Six 10 ICR mice (male, body weight 25-35 g) were intraperitoneally injected with the 10% physiological saline solution of the keratinization-suppressing agent obtained in Example 1 at 1000 mg / Kg, respectively. I made an injection.
Life or death was determined 14 days after administration, but no death was observed. From this, it is understood that the keratinization-promoting agent of the present invention has an LD 50 value of 1000 mg / Kg, and is highly safe.

【0021】実施例3 局所毒性 6匹のハートレー系白色モルモットを用い経皮投与に於
ける、局所毒性を調べた。即ち、モルルモット背部を2
cm四方に除毛し、実施例1の角化亢進抑制剤の10%
水溶液を、毎日0.05ml、5日間投与した。6日目
に皮膚反応を、本邦パッチテスト規準(日本皮膚科学
会)に準じて判定した。即ち、−:無反応、±:疑わし
い陽性反応、+:陽性反応、++:浮腫を伴う反応の4
段階の規準である。結果は何れの動物も無反応(−)で
あった。
Example 3 Local Toxicity Local toxicity in transdermal administration was investigated using 6 Hartley white guinea pigs. That is, 2 backs of morlemot
cm squared, 10% of the hyperkeratosis inhibitor of Example 1
The aqueous solution was administered daily at 0.05 ml for 5 days. On the 6th day, the skin reaction was evaluated according to the Japanese patch test standard (Japan Dermatological Association). That is,-: no reaction, ±: suspicious positive reaction, +: positive reaction, ++: reaction with edema 4
It is a criterion of stage. As a result, all animals showed no reaction (-).

【0022】実施例4 角化亢進抑制作用 角化亢進は、細胞増殖が亢進されて起こるとされている
ため、角化亢進抑制作用のパラメーターに、以下の方法
で求められる試験物質の表皮細胞増殖因子(EGF)に
対する増殖抑制率を用いて評価した。即ち、10%ウシ
胎仔血清(FBS)含有イーグル最小培地(10%FB
S−MEM)0.5ml中に、2.5×104個の線維
芽細胞(balb/c 3T3 cells)を含有す
る溶液を、24穴プレートの各穴にそれぞれ1mlづつ
まいた。線維芽細胞が単層状態で飽和になった後、1%
FBS−MEMに換え、37℃、5%炭酸ガス下で12
時間培養した。その後、この24穴プレートの各穴にマ
ウス由来のEGFを1穴当たり、50pg添加し、実施
例1の角化亢進抑制剤をn=4でそれぞれ1穴当たり
0.5μg添加し、更に16時間培養した。なお、コン
トロールには、マウス由来のEGF以外は添加しなかっ
た。その後、各穴に0.5μCi/50μlづつの3
−チミジンを加え、更に8時間培養した後、培養液を除
去し、冷却した等張燐酸緩衝液にて洗浄し、冷5%トリ
クロロ酢酸を加え30分間放置した。これより上清を除
去し、トリクロロ酢酸沈澱画分を0.5M水酸化ナトリ
ウム溶液に溶解してから、0.5M塩酸で中和し、これ
にシンチレーターを加え、液体シンチレーションカウン
ターでカウントし、増殖に伴って取り込まれた3H−チ
ミジンの放射活性を測定した。ここで、実施例1の角化
亢進抑制剤共存下での細胞内に取り込まれた3H−チミ
ジンの放射活性値の、コントロール培養液で細胞内に取
り込まれた3H−チミジンの放射活性値に対する百分率
を求め、これを増殖抑制率として、EGFによって促進
された細胞の増殖に対する試験物質の細胞増殖抑制効果
を評価した。これより得られた、実施例1の角化亢進抑
制剤の細胞増殖抑制率は73.1%であった。これよ
り、実施例1の角化亢進抑制剤は優れた細胞増殖抑制効
果を有することが判る。
Example 4 Inhibitory effect on keratinization Since keratinization is said to occur due to accelerated cell growth, epidermal cell proliferation of the test substance, which is determined by the following method, as a parameter for the inhibitory effect on keratinization is described. It evaluated using the growth-inhibition rate with respect to a factor (EGF). That is, Eagle's minimum medium containing 10% fetal bovine serum (FBS) (10% FB
A solution containing 2.5 × 10 4 fibroblasts (balb / c 3T3 cells) in 0.5 ml of S-MEM) was added to each well of a 24-well plate in an amount of 1 ml. 1% after fibroblasts become saturated in monolayer
Replace with FBS-MEM, and use 12% under 5% carbon dioxide gas at 37 ° C.
Incubated for hours. Thereafter, 50 pg of mouse-derived EGF was added to each well of this 24-well plate per well, and the keratinization-promoting inhibitor of Example 1 was added at 0.5 μg per well at n = 4, and further for 16 hours. Cultured. In addition, only the mouse-derived EGF was added to the control. Then, 0.5 μCi / 50 μl of 3 H in each hole
-Thymidine was added, and after further culturing for 8 hours, the culture solution was removed, washed with a cooled isotonic phosphate buffer solution, cold 5% trichloroacetic acid was added, and the mixture was allowed to stand for 30 minutes. The supernatant was removed from this, and the trichloroacetic acid precipitate fraction was dissolved in 0.5M sodium hydroxide solution, then neutralized with 0.5M hydrochloric acid, and a scintillator was added to this, counted by a liquid scintillation counter, and grown. The radioactivity of 3 H-thymidine incorporated with the above was measured. Here, the radioactivity values of 3 H- thymidine incorporated into cells at hyperkeratosis inhibitor coexistence of Example 1 was incorporated into the cells in the control culture medium 3 H- radioactivity value thymidine To the growth inhibition rate, and the cell growth inhibition effect of the test substance on the cell growth promoted by EGF was evaluated. The cell proliferation inhibitory rate of the keratinization-promoting inhibitor of Example 1 obtained from this was 73.1%. From this, it is found that the keratinization-promoting inhibitor of Example 1 has an excellent cell growth inhibitory effect.

【0023】実施例5 配合例1(乳液) 下記の処方に従って乳液を作成した。即ち、A、B、C
をそれぞれ80℃で加熱溶解し、AにBを攪はんしなが
ら、徐々に加え、更にCを加え、攪はんしながら冷却し
乳液を得た。 (A)ベヘニルアルコール 0.5 合成ゲイロウ 2.5 オリーブオイル 1.5 ソルビタンモノステアレート 1.5 POE(20)ベヘニルエーテル 2 ブチルパラベン 0.1 BHT 0.1 流動パラフィン 3.5 実施例1の角化亢進抑制剤 0.1 ステアリン酸 0.5 (B)プロピレングリコール 10 メチルパラベン 0.2 苛性カリ 0.1 水 50 (C)カーボポール 0.2 水 27.2
Example 5 Formulation Example 1 (Emulsion) An emulsion was prepared according to the following formulation. That is, A, B, C
Was dissolved by heating at 80 ° C., B was gradually added to A with stirring, C was further added, and the mixture was cooled with stirring to obtain an emulsion. (A) Behenyl alcohol 0.5 Synthetic geyrow 2.5 Olive oil 1.5 Sorbitan monostearate 1.5 POE (20) Behenyl ether 2 Butylparaben 0.1 BHT 0.1 Liquid paraffin 3.5 3.5 Horn of Example 1 Anti-promoting agent 0.1 Stearic acid 0.5 (B) Propylene glycol 10 Methylparaben 0.2 Caustic potassium 0.1 Water 50 (C) Carbopol 0.2 Water 27.2

【0024】実施例6 配合例2(乳液) 下記の処方に従って乳液を作成した。即ち、A、B、C
をそれぞれ80℃で加熱溶解し、AにBを攪はんしなが
ら、徐々に加え、更にCを加え、攪はんしながら冷却し
乳液を得た。 (A)ベヘニルアルコール 0.5 合成ゲイロウ 2.5 オリーブオイル 1.5 ソルビタンモノステアレート 1.5 POE(20)ベヘニルエーテル 2 ブチルパラベン 0.1 BHT 0.1 流動パラフィン 3.6 実施例1の角化亢進抑制剤 5 ステアリン酸 0.5 (B)プロピレングリコール 10 メチルパラベン 0.2 苛性カリ 0.1 水 50 (C)カーボポール 0.2 水 22.2
Example 6 Formulation Example 2 (Emulsion) An emulsion was prepared according to the following formulation. That is, A, B, C
Was dissolved by heating at 80 ° C., B was gradually added to A with stirring, C was further added, and the mixture was cooled with stirring to obtain an emulsion. (A) Behenyl alcohol 0.5 Synthetic geyrow 2.5 Olive oil 1.5 Sorbitan monostearate 1.5 POE (20) Behenyl ether 2 Butylparaben 0.1 BHT 0.1 Liquid paraffin 3.6 Corner of Example 1 Anti-promoting agent 5 Stearic acid 0.5 (B) Propylene glycol 10 Methylparaben 0.2 Caustic potassium 0.1 Water 50 (C) Carbopol 0.2 Water 22.2

【0025】実施例7 配合例3(乳液) 下記の処方に従って乳液を作成した。即ち、A、B、C
をそれぞれ80℃で加熱溶解し、AにBを攪はんしなが
ら、徐々に加え、更にCを加え、攪はんしながら冷却し
乳液を得た。 (A)ベヘニルアルコール 0.5 合成ゲイロウ 2.5 オリーブオイル 1.5 ソルビタンモノステアレート 1.5 POE(20)ベヘニルエーテル 2 ブチルパラベン 0.1 BHT 0.1 流動パラフィン 3.6 実施例1の角化亢進抑制剤 1 ステアリン酸 0.5 (B)プロピレングリコール 10 メチルパラベン 0.2 苛性カリ 0.1 水 50 (C)カーボポール 0.2 水 26.2
Example 7 Formulation Example 3 (Emulsion) An emulsion was prepared according to the following formulation. That is, A, B, C
Was dissolved by heating at 80 ° C., B was gradually added to A with stirring, C was further added, and the mixture was cooled with stirring to obtain an emulsion. (A) Behenyl alcohol 0.5 Synthetic geyrow 2.5 Olive oil 1.5 Sorbitan monostearate 1.5 POE (20) Behenyl ether 2 Butylparaben 0.1 BHT 0.1 Liquid paraffin 3.6 Corner of Example 1 Anti-promoting agent 1 Stearic acid 0.5 (B) Propylene glycol 10 Methylparaben 0.2 Caustic potassium 0.1 Water 50 (C) Carbopol 0.2 Water 26.2

【0026】実施例8 配合例4(乳液) 下記の処方に従って乳液を作成した。即ち、A、B、C
をそれぞれ80℃で加熱溶解し、AにBを攪はんしなが
ら、徐々に加え、更にCを加え、攪はんしながら冷却し
乳液を得た。 (A)ベヘニルアルコール 0.5 合成ゲイロウ 2.5 オリーブオイル 1.5 ソルビタンモノステアレート 1.5 POE(20)ベヘニルエーテル 2 ブチルパラベン 0.1 BHT 0.1 流動パラフィン 3.6 実施例1の角化亢進抑制剤 5 実施例5のシワ改善剤 5 ステアリン酸 0.5 (B)プロピレングリコール 10 メチルパラベン 0.2 苛性カリ 0.1 水 50 (C)カーボポール 0.2 水 17.2
Example 8 Formulation Example 4 (Emulsion) An emulsion was prepared according to the following formulation. That is, A, B, C
Was dissolved by heating at 80 ° C., B was gradually added to A with stirring, C was further added, and the mixture was cooled with stirring to obtain an emulsion. (A) Behenyl alcohol 0.5 Synthetic geyrow 2.5 Olive oil 1.5 Sorbitan monostearate 1.5 POE (20) Behenyl ether 2 Butylparaben 0.1 BHT 0.1 Liquid paraffin 3.6 Corner of Example 1 Anti-promoting agent 5 Wrinkle improver of Example 5 5 Stearic acid 0.5 (B) Propylene glycol 10 Methylparaben 0.2 Caustic potash 0.1 Water 50 (C) Carbopol 0.2 Water 17.2

【0027】実施例9 配合例5(クリーム) 下記の処方に準じてクリームを作成した。即ち、A、B
をそれぞれ80℃に加熱溶解して、AにBを攪はんしな
がら徐々に加え、冷却してクリームを得た。 (A)ベヘニルアルコール 6 オリーブオイル 6 水添牛脂 2 マイクロクリスタリンワックス 6 流動パラフィン 20 ステアリン酸 4 グリセリルモノステアレート 2.5 POE(20)ベヘニルエーテル 1.5 ミツロウ 2 塩化ベンザルコニウム 0.1 実施例1の角化亢進抑制剤 5 (B)プロピレングリコール 10 苛性カリ 0.1 水 36.8
Example 9 Formulation Example 5 (Cream) A cream was prepared according to the following formulation. That is, A, B
Were dissolved by heating at 80 ° C., B was gradually added to A while stirring, and cooled to obtain a cream. (A) Behenyl alcohol 6 Olive oil 6 Hydrogenated beef tallow 2 Microcrystalline wax 6 Liquid paraffin 20 Stearic acid 4 Glyceryl monostearate 2.5 POE (20) Behenyl ether 1.5 Beeswax 2 Benzalkonium chloride 0.1 Example 1 Keratinization inhibitor 5 (B) propylene glycol 10 caustic potash 0.1 water 36.8

【0028】実施例10 使用テスト 実施例5の乳液を用いて使用テストを行った。即ち、肌
荒れに悩む女性パネラー1群20名(年齢35〜70
才)を用いて、実施例10の乳液と、比較例として実施
例5の乳液中の角化亢進抑制剤を水に置き換えたものに
ついて、肌荒れ改善効果を調べた。これらの乳液は1日
2回30日連続使用し、使用前と使用後について皮膚の
状態を写真に取り、改善度を次の基準で判定した。ー:
変化無しまたは悪化、±:やや改善、+:明らかな改
善、++:著しい改善の基準である。結果を表1に示
す。本発明の角化亢進抑制剤による肌荒れ改善効果が明
らかである。
Example 10 Use Test A use test was conducted using the emulsion of Example 5. That is, a group of 20 female panelists suffering from rough skin (age 35-70)
, The effect of improving rough skin was examined for the emulsion of Example 10 and the emulsion of Example 5 in which the keratinization-promoting inhibitor in Example 5 was replaced with water. These emulsions were used twice a day for 30 consecutive days, and the skin condition was photographed before and after use, and the degree of improvement was judged according to the following criteria. -:
No change or deterioration, ±: Slight improvement, +: Clear improvement, ++: Significant improvement. The results are shown in Table 1. It is clear that the keratinization-promoting agent of the present invention has an effect of improving rough skin.

【0029】[0029]

【表1】 [Table 1]

【0030】実施例11 使用テスト 実施例9のクリームについて、実使用テストを行い、肌
荒れ改善効果について確かめた。即ち、肌荒れに悩む女
性パネラー20名(年齢40〜65才)を用い、10名
づつ2群に分け、1群には実施例9のクリームを、もう
1群には実施例9のクリームの実施例1の角化亢進抑制
剤をオリ−ブオイルに替えた比較例のクリームを渡し、
3カ月1日2回連続使用してもらった。その後肌荒れの
改善度をアンケートにより調べた。結果を表2に示す。
これより、実施例のクリームの方が比較例のクリームよ
り肌荒れを改善していることが判る。従って、本発明の
角化亢進抑制剤が優れた肌荒れ改善作用を有することが
明かである。
Example 11 Use Test The cream of Example 9 was subjected to an actual use test to confirm the effect of improving rough skin. That is, 20 female panelists (aged 40 to 65 years old) suffering from rough skin are used and divided into 2 groups of 10 persons, one group containing the cream of Example 9 and the other group containing the cream of Example 9. The cream of Comparative Example in which the hyperkeratosis inhibitor of Example 1 was replaced with olive oil was given,
I had it used twice a day for 3 months continuously. After that, the degree of improvement in rough skin was examined by a questionnaire. The results are shown in Table 2.
From this, it can be seen that the creams of Examples have improved rough skin compared to the creams of Comparative Examples. Therefore, it is clear that the keratinization-promoting agent of the present invention has an excellent effect of improving rough skin.

【0031】[0031]

【表2】 [Table 2]

【0032】[0032]

【発明の効果】本発明の角化亢進抑制剤は安全性が高い
上に肌荒れ改善作用に優れているので、化粧料の成分と
して大変有用である。
INDUSTRIAL APPLICABILITY The keratinization-promoting agent of the present invention is highly useful as a component of cosmetics because it is highly safe and has an excellent effect of improving skin roughness.

───────────────────────────────────────────────────── フロントページの続き (72)発明者 山本 信 神奈川県横浜市柏尾町560番地 ポーラ化 成工業株式会社戸塚研究所内 (72)発明者 宮瀬 敏男 静岡県静岡市中田4丁目5−29番地 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Nobu Yamamoto No. 560 Kashio-cho, Yokohama-shi, Kanagawa Pola Chemical Industry Co., Ltd. Totsuka Laboratory (72) Inventor Toshio Miyase 4-chome, Nakata, Shizuoka, Shizuoka

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】 構造式化1に示される1、2−ジヒドロ
キシ−4−(2−ヒドロキシエチル)ベンゼン及び/ま
たはその塩からなる角化亢進抑制剤。 【化1】
1. A keratinization-promoting agent comprising 1,2-dihydroxy-4- (2-hydroxyethyl) benzene represented by Structural Formula 1 and / or a salt thereof. [Chemical 1]
【請求項2】 請求項1記載の角化亢進抑制剤を0.0
1〜10重量%含有する皮膚外用剤。
2. The anti-keratinization inhibitor according to claim 1, which is 0.0
An external preparation for skin containing 1 to 10% by weight.
JP3308494A 1994-02-04 1994-02-04 Skin external agent Pending JPH07215837A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP3308494A JPH07215837A (en) 1994-02-04 1994-02-04 Skin external agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3308494A JPH07215837A (en) 1994-02-04 1994-02-04 Skin external agent

Publications (1)

Publication Number Publication Date
JPH07215837A true JPH07215837A (en) 1995-08-15

Family

ID=12376836

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3308494A Pending JPH07215837A (en) 1994-02-04 1994-02-04 Skin external agent

Country Status (1)

Country Link
JP (1) JPH07215837A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032966A1 (en) * 2001-10-09 2003-04-24 Fancl Corporation Compositions for potentiating glutatthione
JP2003146870A (en) * 2001-11-09 2003-05-21 Kanebo Ltd Lipid degradation promoter and method of slimming body

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032966A1 (en) * 2001-10-09 2003-04-24 Fancl Corporation Compositions for potentiating glutatthione
US7740831B2 (en) 2001-10-09 2010-06-22 Fancl Corporation Compositions for potentiating glutathione
JP2003146870A (en) * 2001-11-09 2003-05-21 Kanebo Ltd Lipid degradation promoter and method of slimming body

Similar Documents

Publication Publication Date Title
JP2003113068A (en) Skin cosmetic
KR100977672B1 (en) Cosmetic composition for anti-aging comprising the cellular vital complex as active ingredient
JPH11255639A (en) Tyrosinase activity inhibitor and cosmetic
JPH11255638A (en) Tyrosinase activity inhibitor and cosmetic
US20170266157A1 (en) Methods for wound healing and scar prevention
EP0968221B1 (en) Novel salicylic acid derivatives and their use in cosmetic or dermatological compositions
JP3403780B2 (en) Cosmetics
JPH07215837A (en) Skin external agent
JP4413387B2 (en) Collagen production promoter, elastase activity inhibitor, collagenase activity inhibitor and skin cosmetic
KR101140573B1 (en) External Skin Preparation Using an Extract of Horse Plancenta
JPH1180105A (en) N-acylamino acid and cosmetic using the same
JP2013166732A (en) Method for producing endothelin activity inhibitor and method for producing usnea longissima extract
JP2001162103A (en) Method for extracting plant essence and ointment containing the plant essence
JP2011111416A (en) Semaphorin expression enhancer
JP3023543B2 (en) Tyrosinase activity inhibitor and cosmetic
JP2003095859A (en) Pigmentation inhibitor, method for producing the same and use thereof
KR102415530B1 (en) Composition for moisturizing skin
JP2884166B2 (en) Anti-dermatophyte
JP3754945B2 (en) Skin preparation for beautifying skin
JP2003306421A5 (en)
JP2005170918A (en) Skin care preparation for external use
JP3337845B2 (en) Hair restoration composition
JP2023510655A (en) Composition for suppressing aging odor containing arginine aspartate
JP4245862B2 (en) Topical skin preparation
JP6345537B2 (en) Skin external preparation or internal preparation